Gastric Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Gastric Cancer Market Outlook

Thelansis’s “Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastric Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Gastric Cancer Overview

Gastric cancer ranks the fourth most prevalent malignancy among men and the seventh among women. In the context of this disease, fibroblast growth factors (FGFs) play a critical role by binding to FGFR, subsequently leading to phosphorylation at intracellular tyrosine residues. This, in turn, triggers downstream signaling activation. In roughly 30% of gastric carcinomas, there is an observable overexpression of the FGFR2 protein. This overexpression correlates positively with scirrhous cancer, a diffuse type of cancer, invasion depth, infiltration type, and a less favorable prognosis. Approximately 5-10% of gastric cancer patients exhibit amplification of FGFR2. Several factors are associated with an elevated risk of developing gastric cancer. These factors encompass dietary elements such as high-salt intake from salt-preserved foods, consumption of N-nitroso compounds from dietary sources, smoking, inadequate intake of vitamins A and C, excessive consumption of smoked or cured foods, insufficient consumption of refrigerated foods, and exposure to contaminated drinking water. Furthermore, an increased body mass index (BMI), higher calorie consumption, gastroesophageal reflux, and smoking are all linked to a heightened risk of adenocarcinomas affecting the distal esophagus, proximal stomach, and junction. The choice of treatment for gastric cancer hinges on the precise preoperative staging. Therapeutic options encompass endoscopic resection for superficial disease confined to the mucosa (< T1b, N0), upfront surgical resection with lymphadenectomy (< T3, any N), neoadjuvant therapy for cases exceeding T2, adjuvant therapy for cases falling within > T1N1 or > T3N0, radiation therapy, or a combination of these modalities for resectable lesions. For individuals with locally advanced unresectable or metastatic disease (T4, any N, or M1), palliative systemic therapy is considered.

• The annual incidence of gastric cancer is 6.9 cases per 100,000 men and women per year.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: